Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8485796 | Vaccine | 2018 | 10 Pages |
Abstract
Both CYD-TDV and NVC could be cost-effective at the DALY threshold cost of $2000 depending upon vaccination costs. With CYD-TDV, targeting 9â¯year olds in routine vaccination programs and 10-29â¯year olds as a one-off catch-up campaign was the most cost-effective strategy in all three countries. With NVC, while the most cost-effective strategy was to vaccinate 9-29 and 9-18â¯year olds in Vietnam and Thailand respectively, vaccinating younger age cohorts between 1 and 5â¯years old in Colombia was more cost-effective than other strategies. Given that three countries will soon face decisions regarding whether and how to incorporate CYD-TDV or future dengue vaccines into their budget-constrained national immunization programs, the current study outcomes can be used to help decision makers understand the expected impacts and cost-effectiveness of such vaccines.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jung-Seok Lee, José Lourenço, Sunetra Gupta, Andrew Farlow,